Parallax Volatility Advisers, L.P. Argenx Se Call Options Transaction History

Parallax Volatility Advisers, L.P.

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$434.22 - $551.9 $1.91 Million - $2.43 Million	4,400 Added 23.4%	23,200 $12.6 Million
Q2 2024 Aug 14, 2024	BUY	$356.01 - $451.55 $4.17 Million - $5.28 Million	11,700 Added 164.79%	18,800 $8.08 Million
Q1 2024 May 15, 2024	BUY	$356.95 - $413.29 $2.53 Million - $2.93 Million	7,100 New	7,100 $2.8 Million
Q2 2022 Aug 15, 2022	SELL	$269.58 - $378.88 $5.8 Million - $8.15 Million	-21,500 Reduced 68.25%	10,000 $3.79 Million
Q3 2021 Nov 15, 2021	BUY	$295.0 - $350.58 $9.06 Million - $10.8 Million	30,700 Added 3837.5%	31,500 $9.51 Million
Q3 2020 Nov 13, 2020	BUY	$215.51 - $272.51 $172,408 - $218,008	800 New	800 $211,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.